A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma. (April 2016)

• Record Type: Journal Article
• Authors: Odia, Yazmin; Sul, Joohee; Shih, Joanna H; Kreisl, Teri N; Butman, John A; Iwamoto, Fabio M; Fine, Howard A
• Is Part Of: CNS oncology. Volume 5:Number 2(2016)
• Page Start: 59
• Page End: 67
• Publication Date: 2016-04
• Subjects: bevacizumab -- glioblastoma -- tandutinib; Central nervous system -- Tumors -- Periodicals; 616.99481
• DOI: 10.2217/cns-2015-0010
• Languages: English
• ISSNs: 2045-0907

Abstract

Aim: A Phase II trial of bevacizumab plus tandutinib.Methods: We enrolled 41 recurrent, bevacizumab-naive glioblastoma patients for a trial of bevacizumab plus tandutinib. Median age was 55 and 71% were male. Treatment consisted of tandutinib 500 mg two-times a day (b.i.d.) and bevacizumab 10 mg/kg every 2 weeks starting day 15. Of 37 (90%) evaluable, nine (24%) had partial response.Results & conclusion: Median overall and progression-free survival was 11 and 4.1 months; progression-free survival at 6 months was 23%. All patients suffered treatment-related toxicities; common grade ≥3 toxicities were hypertension (17.1%), muscle weakness (17.1%), lymphopenia (14.6%) and hypophosphatemia (9.8%). Four of six with grade ≥3 tandutinib-related myasthenic-like muscle weakness had electromyography-proven neuromuscular junction pathology. Tandutinib with bevacizumab was as effective but more toxic than bevacizumab monotherapy.